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Abstract
Background: Huntington disease (HD) is associated with increased risk of suicide.

Author Manuscript

Objective: This study compares suicide ideation in HD to the general population, assesses
factors associated with increased prevalence of suicidal thoughts, and compares clinician-rated to
self-reported assessments of suicidal ideation.
Methods: We examined 496 participants with premanifest or manifest HD. Clinician-rated
suicidal ideation was measured using the Problem Behaviors Assessment – short form. Selfreported ideation was measured using two items from the HDQLIFE Concern with Death and
Dying item bank. Independent sample t-tests were conducted to compare the prevalence of
suicidal thoughts between our HD sample and the U.S. population. Logistic regression analyses
were used to determine characteristics associated with higher odds of clinically significant suicidal
ideation. Kappa agreement coefficients were calculated to evaluate concurrence between clinicianrated and self-reported assessments.

Author Manuscript

Results: Our sample had a significantly higher occurrence of suicidal ideation (19.76%) and
suicidal plans (2.1%) than the general population (p < 0.0001). Odds of clinically significant
suicidal ideation were 6.8 times higher in females (p = 0.04) on the clinician measure, and
Hispanic/Latinos had 10.9 times higher odds than non-Hispanics (p = 0.025) on the self-report
measure. Clinician-rated assessment had fair agreement (k = 0.2–0.4) with self-reported
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assessments, except in early stage HD where there was no overlap in the identification of
participants with clinically significant suicidal ideation.
Discussion: Assessment for suicidal ideation and clinically significant suicidal thoughts in HD
with a multimodal approach that includes clinician-rated and self-report measures is critical at all
stages of the disease.
Keywords
Huntington disease; suicidal ideation; suicide; suicide assessment; comparing methods

INTRODUCTION
Author Manuscript

Huntington disease is an autosomal dominant, inherited, neurodegenerative disorder
associated with an increased risk of suicidal ideation [1, 2]. This increased risk of suicide
occurs through all stages of the disease, from the premanifest phase through onset of
symptoms and continues as the disease progresses [3]. Opportunities to assess at-risk
individuals for suicide and relevant risk factors occur at the time of predictive testing, during
clinical care, and during participation in clinical research. The current study sought to
evaluate suicide ideation in clinical research participants in the Huntington Disease HealthRelated Quality of Life (HDQLIFE) Study [4], and compare the rates of suicidal thoughts
and clinically significant ideation to the general population, assess factors associated with an
increased risk for suicidal ideation, and compare in-person clinician assessment of suicide
ideation with a self-reported online assessment tool.

Author Manuscript

Huntington disease (HD) affects between 3 and 10 individuals per 100,000 worldwide [5, 6],
and causes chorea, cognitive impairment, behavior changes, and psychiatric symptoms [2,
7]. The pathogenic gene mutation is located at 4p16.3 and contains an expanded CAG repeat
in exon 1 in individuals with HD [8, 9]. Average diagnosis is in the late 30 s, with the age of
onset inversely related to the number of CAG repeats. Symptoms typically emerge gradually,
with behavioral and cognitive symptoms commonly occurring years before motor symptoms
[10]. Death occurs 15–20 years after symptom onset/diagnosis [2, 11, 12].
George Huntington’s original description in 1872 included a “tendency to insanity and
suicide” as one of the peculiarities of the disease, and he comments that he was aware of
several instances of suicide in affected and at-risk family members [13]. Reported suicide
rates vary from 5.7% in affected persons [1] to 7.3% in affected and at-risk participants [14].
Farrer [1] reported that 27.6% of patients had attempted suicide at least once, which exceeds
the general US population lifetime prevalence of 1.9–8.7% for suicide attempts [15].

Author Manuscript

Assessment of suicide risk can occur via an in-person clinical interview or completion of a
self-report instrument. While many studies in HD utilize either the Problem Behaviors
Assessment-short (PBA-s; 16) or the Columbia Suicide Severity Rating Scale (CSSRS; 17),
there is no consensus for which measure should be used, nor are there standardized follow
up procedures when someone at high risk is identified.
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Additionally, clinician assessment may differ from self-reported suicide ideation. For
example, one study found that individuals presenting for their first visit to a clinic for
anxiety and depression were more likely to endorse current suicidal ideation on the selfadministered questionnaire than the clinician interview [18]. Similarly, a self-report
questionnaire also was more likely to reveal increased frequency and severity of suicidal
ideation than an in-person clinician interview in individuals with major depressive disorder
or bipolar disorder [19]. In contrast, clinicians rated suicide ideation higher than self-report
in patients referred from Army hospitals for depression or anxiety [20]. Furthermore,
clinician interview assessments of suicidal ideation varied from self-reported suicidal
thoughts by 19% in a study of patients admitted to an adult inpatient psychiatric unit that
treated primarily mood, anxiety, eating and adjustment disorders [21]. These mixed findings
suggest that the mode of assessment (either by self-report or through an in-person interview)
may have an impact of how willing an individual is to report suicidal thoughts. Thus, a better
understanding of the assessment modality in HD may help inform best practices with regard
to suicidal ideation and suicide assessment in these individuals.

Author Manuscript
Author Manuscript

The purpose of this paper is to examine suicidal ideation, as well as the impact of
assessment modality (in-person versus self-report survey assessment) in HD. Specifically,
we hypothesized that the rates of suicidal ideation and clinically significant suicidal ideation
in premanifest and manifest HD would exceed that of the general population. In addition, we
hypothesized that individuals who are later in the disease process, as well as those with more
clinician-rated depression, anxiety and/or anger would exhibit more severe suicidal ideation
[22, 23]. We also hypothesized that the demographic differences in the general population
(e.g., females have a higher prevalence of suicidal thoughts, but not suicidal plans) [24] also
would occur in HD. Finally, we hypothesized that frequency of self-reported suicidal
thoughts would be higher than frequency of clinician-rated suicidal ideation.

METHODS
Participants

Author Manuscript

We examined individuals with either premanifest (gene-positive for the HD CAG expansion
and no clinical diagnosis) or manifest HD. Participants had to be at least 18 years of age,
able to read and understand English, and have the ability to provide informed consent.
Participants were recruited from several HD treatment centers (the University of Michigan,
University of Iowa, University of California-Los Angeles, Indiana University, Johns Hopkins
University, Rutgers University, Struthers Parkinson’s Center, and Washington University), as
well as through the National Research Roster for Huntington Disease Patients and Families
at Indiana University, existing online medical record data capture systems [25], and the
Predict-HD study [26]. All data were collected in accordance to local Institutional Review
Boards (IRB) and participants provided informed consent prior to study participation.
HD disease stage
The final item of the Unified Huntington Disease Rating Scale (UHDRS; 27) motor
assessment was used to differentiate premanifest from manifest HD. This item indicates the
“diagnostic confidence level” on a scale of 0 (no motor abnormalities) to 4 (>99%
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confidence that motor abnormalities are unequivocal signs of HD) of the clinician’s
impression of whether or not the participant has manifest HD. Scores lower than 4 indicate
premanifest HD whereas a score of 4 indicates manifest HD. For manifest participants, the
UHDRS Total Functional Capacity (TFC) was used to determine HD staging [28]. TFC is a
clinician-rated assessment of a participant’s ability to maintain a job, manage finances
independently, complete chores, accomplish activities of daily living [29], and live at home
as opposed to a nursing or chronic care facility. TFC scores range from 0–13 with higher
scores indicative of higher functioning. Stage I was defined as individuals with TFC scores
ranging from 11–13, and Stage II was defined as individuals with TFC scores ranging from
7–10. Stages III to V were collapsed together into one group, which was defined by a score
of 0–6 [28].
Comparisons with the United States average

Author Manuscript

Rates of suicidal ideation and suicide planning within our sample were compared to
published data from reports from the National Survey on Drug Use and Health from the
Centers for Disease Control and Prevention [CDC], examining suicidal thoughts in the
general population [24]. Respondents were asked whether they had seriously thought about
killing themselves at any time during the past 12 months. If participants answered in the
affirmative, they were then asked whether they had made any plans to kill themselves and
whether they had a suicide attempt. With this information, the CDC article estimates the
prevalence of suicidal thoughts and behaviors based on survey data from 8,360 respondents
from 2008–2009.
Clinician-rated behaviors and suicidal ideation

Author Manuscript
Author Manuscript

Problem Behaviors Assessment – short (PBA-s; 16).—The PBA-s is a clinicianrated measure of behavioral problems based on a semi-structured interview with patients and
informants designed specifically for HD. Clinician raters were trained on this measure and
required to demonstrate proficiency in its administration. It includes 11 items that examine
different aspects of emotion and behavior including depression, suicidal ideation, anxiety,
irritability, anger/aggression, apathy, perseverative thinking, obsessive compulsive behaviors,
delusions, hallucinations, and disorientation. Clinicians rate each item for severity (rated on
a scale of 0 [symptom absent] to 4 [severe] and frequency (rated on a scale of 0 [never/
almost never] to 4 [daily/almost daily for most or all of the day]). We examined frequency of
suicidal thoughts in premanifest and manifest HD participants compared to the U.S. average,
as well as agreement between clinician-rated and self-reported measures. Severity scores
were utilized in our assessment of clinically significant individuals, which we defined as
participants who had persistent suicidal ideation or have made preparations or an attempt to
commit suicide. Participants with ratings of ≥3 for suicide severity were considered
clinically significant, defined as severe ideation that includes a plan or prior attempt of
suicide. For these participants, additional follow-up questions were asked to determine
imminent risk and/or if additional referrals or treatment were warranted. Clinically
significant suicidal ideation was coded as a dichotomous variable, either ‘Yes’ for
participants with clinically significant suicidal ideation or ‘No’ for participants who were
not. This variable was compared to the national U.S. estimates of individuals with a suicide
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plan, and was also used to measure agreement between clinician-rated and self-reported
clinically significant individuals.
Self-reported suicidal ideation

Author Manuscript

As part of a larger study, participants completed an online survey that examined their healthrelated quality of life (HRQOL; details reported in 4). This study included two questions that
assess suicidal thoughts (these items were administered as part of the HDQLIFE Concern
with Death and Dying measure; [30]. The first question read “In the past seven days, how
often have you thought about ending your life?” Responses were on a 5-point Likert scale
ranging in frequency from ‘Never’ to ‘Always.’ Similar to the clinician-rated measures, selfreported frequency of suicidal thoughts was compared to U.S. estimates. For all responses
that were not ‘Never,’ a follow-up question was administered: “Do you intend to act on these
thoughts in the near future?” Responses of ‘Yes’ were considered clinically significant
(defined below). Clinically significant responses, as determined by the self-report measure,
were compared to the U.S. estimate of the prevalence of individuals who have a suicide plan.
Clinically significant suicidal thoughts

Author Manuscript

Participants who received a severity score greater than or equal to 3 on the suicide-specific
question on the PBAs, or who indicated ‘yes’ to the following question on HDQLIFE
Concern with Death and Dying, “Do you intend to act on these thoughts in the near future?”
were considered clinically significant, and required additional follow-up (as per the suicide
assessment protocol associated with this study). The suicide protocol dictated that further
questions to establish imminent risk were employed through direct contact (by phone or inperson) between the study investigator or coordinator and participant. Specifically, follow-up
questions with regard to suicidal thoughts (including frequency and persistence of these
thoughts), details with regard to a plan, identification of future reasons to live, as well as
previous history of attempts were queried to determine if there was imminent risk. In all
cases of endorsement, the study site investigator was notified, consulted, and follow-up
actions documented. In cases where imminent risk was identified the study site investigator
made the appropriate referrals following professional standards of conduct, including
contacting emergency services if needed.
Analysis plan
Frequency counts for endorsement of the suicide assessment items on the PBA-S and the
two self-report suicidal ideation questions from the Concern with Death and Dying measure
were calculated using SAS 9.4.

Author Manuscript

Suicidal ideation prevalence in HD relative to the U.S general population
Four separate independent sample t-tests were conducted to compare the prevalence of
suicidal thoughts between the CDC’s U.S. average and our sample. The first two t-tests
compared the proportion of individuals with suicidal ideation between the U.S. population
and our measures (i.e., the PBA-s and HDQLIFE survey) of suicide frequency in HD. For
these tests, our frequency measures were dichotomized into “no suicide ideation” or “suicide
ideation present.” Another t-test compared rates of individuals in our cohort with persistent
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suicidal ideation and/or plans to act on these thoughts in the future, with rates of individuals
within the U.S. population with suicidal thoughts. A final t-test compared the proportion of
HD participants who were clinically significant based on our measures of suicidal ideation
(i.e., PBA-s and HDQLIFE survey) to the proportion of individuals within the U.S.
population with a suicide plan.
Demographic risk factors for suicidal ideation in HD

Author Manuscript

In addition, crude and adjusted logistic regression analyses were used to determine which
characteristics relate to higher odds of an individual having clinically significant suicidal
ideation. First, we wanted to determine if the demographic factors (i.e., gender, age, race,
and ethnicity) related to increased odds of having a suicide plan (CDC Morbidity and
Mortality Weekly Report; MMWR) [24] were present in our HD sample. Each of these
demographic variables were entered individually into a logistic model with the outcome of
clinically significant suicidal ideation. Next, logistic regression models determined if staging
and PBA-s total scores of depression, anxiety, and anger/aggression relate to higher odds of
clinically significant suicidal ideation. These variables were selected based upon the
established relationship between emotional distress and suicidal ideation [22, 23].
Concordance between self-reported and clinician-rated suicidal ideation

Author Manuscript

Next, a Kappa agreement coefficient [31] was used to evaluate agreement between the
frequency of the clinician-rated suicide assessment (i.e., PBA-s), and self-report questions.
In addition, Kappa coefficients were used to examine agreement between suicide protocol
activation based on the clinician-rated questions, compared to suicide protocol activation
based on the self-report questions. A kappa score between 0.81 and 1.00 was considered
almost perfect agreement, 0.61–0.80 was considered substantial agreement, 0.41–0.60 was
moderate agreement, 0.21–0.40 was deemed fair agreement, and lower than 0.20 indicated
no agreement [31, 32]. Paired t-tests comparing frequency scores for self-report and
clinician rated measures were used to determine whether one measure had a higher average
score than the other.

RESULTS
Participants

Author Manuscript

We examined 496 individuals with either premanifest (n = 194) or manifest HD (Stage I n =
79; Stage II n = 113; and Stage III-V n = 110; Table 1). Groups did not differ on gender (χ23
= 5.02, p = 0.1705), but, as expected, age differed (F[3, 492] = 29.31, p < 0.0001). The
average age of the premanifest group x = 42.7 was nine years younger than the Stage I
group x = 51.1 , 10 years younger than the Stage II group x = 52.4 , and 13 years younger
than the Stage III-V group x = 54.7 . This finding is expected, as symptoms of HD progress
over time [2]. The Stage III-V group included a greater proportion of African Americans
than the premanifest and Stage I and Stage II groups (Fisher’s Exact = 0.0013), whereas
ethnicity did not differ across groups (χ26 = 11.10, p = 0.09). Education differed between
the four HD groups (F[3, 490] = 12.21, p < 0.0001), as the pre-manifest group had more
years of education than the Stage II and Stage III-V groups. Additionally, the Stage III-V
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group had a higher number of CAG repeat lengths than the premanifest group (F[3,381] =
4.93; p = 0.0023).
Suicidal ideation prevalence in HD relative to the U.S general population

Author Manuscript

Published rates of suicidal thoughts in individuals over the age of 18 in the US indicate that
approximately 3.7% (95% CI: 3.5, 3.9) of individuals endorse suicidal thoughts and 1%
(95%CI: 0.9, 1.1) have a suicide plan [24]. Our self-report measure revealed that 19.76%
(95%CI: 16.3, 23.2) of participants endorsed some degree of suicidal thoughts, which
exceeded the US average [t(8853) = 35.0186; p < 0.0001]. Similarly, our survey indicated
that 2.01% (95% CI: 0.8, 3.2) of our sample planned to act on these thoughts in the near
future, which is significantly higher than the US average (t[2757] = 427.04; p < 0.0001). The
clinician rated measure showed a 11.10% (t[8853] = 35.02; p < 0.0001) prevalence of
suicidal ideation with approximately 2.42% (t[2757] = 425.02; p < 0.0001) of participants
endorsing intention to act on these thoughts in the near future.
Demographic risk factors for suicidal ideation in HD

Author Manuscript

For clinician-rated suicidal ideation, females had a 6.8 times (OR = 7.88, 95% CI: 1.01,
61.554; p = 0.04; Table 2) greater risk of clinically significant suicidal ideation than males,
similar to the U.S. population. However, this finding did not remain significant when
controlled for depression, anger and anxiety. None of the other demographic variables (i.e.,
race, ethnicity, age, or education) significantly related to clinically significant suicidal
ideation. Late-stage participants did not have greater risk of clinically significant ideation
than either early-stage or premanifest participants. Higher levels of clinician rated
depression (OR = 1.47, 95% CI:1.28, 1.70; p < 0.0001), anger (OR = 1.30, 95% CI: 1.14,
1.49; p < 0.0001), and anxiety (OR = 1.28, 95% CI: 1.13,1.44; p < 0.0001) indicated greater
risk of clinically significant suicidal ideation. In the adjusted model, clinician-rated
depression (OR = 1.44, 95% CI: 1.21,1.71; p < 0.0001) was associated with clinically
significant suicidal ideation. However, anger/aggression (OR = 1.21, 95% CI: 1.00, 1.46; p =
0.05), anxiety (OR = 1.01, 95% CI: 0.87, 1.18; p = 0.85) and female gender (OR = 8.21,
95% CI: 0.88, 76.53; p = 0.06) did not.

Author Manuscript

Based upon self-reported suicidal thoughts, ethnicity was the only demographic variable to
have an association with clinically significant suicide ideation in our HD group which differs
from demographic differences in suicidal ideation in the US population. Participants who
identified as Hispanic or Latino had a 10.9 (OR = 10.9, 95% CI: 1.33, 86.88; p = 0.03) times
higher risk of clinically significant suicidal ideation than non-Hispanics or Latinos.
Depression was a significant risk factor of suicidal ideation as well (OR = 1.19, 95% CI:
1.02, 1.38; p < 0.0001), but neither anxiety nor anger/aggression were associated with
clinical significance. In an adjusted model, both depression (OR = 1.18, 95% CI: 1.01, 1.38;
p = 0.04) and ethnicity (OR = 9.23, 95% CI: 1.08, 78.53; p = 0.04) remained significant.
Concordance between self-reported and clinician-rated suicidal ideation
Clinician-rated suicidal ideation—Overall, 11.10% of all participants had a score
higher than 0 (Never) on the suicidal thoughts question of the PBA-s (Table 3). The
frequency of suicidal ideation did not differ among the four HD groups (Fisher’s Exact p =
J Huntingtons Dis. Author manuscript; available in PMC 2019 January 01.
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0.61 Table 3). Overall, we enacted our suicide protocol for 2.27% of the sample based upon
the clinician-rated measure(s). Suicide protocol activation also did not differ among the four
HD groups (Fisher’s Exact p = 0.66; Table 3).
Self-reported suicidal ideation—Overall, 19.76% of participants endorsed suicide
ideation on the self-report assessments (Table 3). Suicide endorsement did not differ among
the four HD groups (Fisher’s Exact p = 0.28; Table 3). Overall, we enacted our suicide
protocol for 1.99% of our study participants based upon the self-report measure(s). The
suicide protocol activation did not differ among the four HD groups (Fisher’s Exact p =
0.57; Table 3).

Author Manuscript

Comparisons between clinician-rated and self-report measures—Of the five
Stage I and three Stage II participants who were clinically significant, four were indicated
solely by the clinician measure and four were indicated solely by the self-report measure,
with no overlap. This indicates that for Stage I and Stage II individuals, the two measures of
clinically significant suicide ideation did not agree (κ = -0.1538 and -0.0541, respectively;
Table 4). The remaining Kappa coefficients indicated that the clinician measure of suicidal
ideation and the self-report measure had fair agreement (κ = 0.2–0.4) for suicide frequency
and clinically significant risk. The exception to this was in the premanifest participants, in
which there was substantial agreement between the two measures of clinically significant
suicidal ideation (κ = 0.6296; Table 4). Participants typically reported greater frequency of
suicidal ideation during the survey than on the clinician measure (t[495] = -5.02; p <
0.0001).

DISCUSSION
Author Manuscript
Author Manuscript

This study confirms that individuals with premanifest and manifest HD have rates of suicidal
ideation and having a suicide plan higher than the general population [24]. In fact, rates for
self-reported suicidal ideation were more than five times greater than rates in the general
population (19.76% in HD relative to 3.7% in the general population). Furthermore, the rate
of individuals with HD that had a plan for suicide was two times that of the general
population (2.01% in HD relative to 1% in the general population). Findings were similar,
although less robust, for clinician-rated suicidal ideation. In this case, clinicians indicated a
prevalence rate of 11.10% for suicidal ideation for these same individuals (relative to the
19.76% based on self-report data). These findings are consistent with previous findings of
suicidal ideation estimates in this population [33–35]. Clinician-rated measures of suicide
plans were comparable to the self-report measures (2.42% for clinician-rated versus 2.01%
for self-reported rates), however, for participants in Stage I and Stage II the two measures
did not overlap. One explanation could be that the self-reported measure asks about suicide
ideation in the past seven days, whereas the clinician-rated measure asks participants about
their situation within the past month, which increases the risk for recall bias. The receipt of a
clinical diagnosis is an emotionally tumultuous time that may enhance variability of
reporting suicidal ideation.
In addition to the general rates for suicidal ideation and suicide plans, we examined different
risk factors for clinically significant suicidal ideation. First, findings suggested that females
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were more likely than males (6.8% more likely) to report clinician-rated, but not selfreported, clinically significant suicidal ideation. While the finding for clinician-rated risk is
consistent with findings in the general population (which also suggest that females have a
higher prevalence than males in regards to suicidal thoughts; 24), the absence of this finding
for self-reported risk was more surprising.

Author Manuscript

Second, none of the other demographic factors that relate to risk in the general population
were found with clinician-rated risk (i.e., that suicidal thoughts and plans are more prevalent
in individuals aged 18–29 [than older participants], in non-Hispanic whites [relative to other
races/ethnicities], and in those with a high school education [relative to those with more
education. Being Hispanic or Latino related to increased risk with the self-report measure, in
contrast to the general population [24]. This unexpected finding seems to contrast with
studies that reported lower suicide rates in Hispanics relative national (US) rates for
Hispanics, [36] as well as similar rates of lifetime suicide attempt among whites, blacks and
Hispanics [37]. To the best of our knowledge, there have been no studies that examined
suicidal ideation in Hispanics living with chronic conditions, which may provide a potential
explanation for this finding. Given the small number of Hispanic or Latino participants in
our study (n = 12), further investigation is warranted.

Author Manuscript

Third, contrary to our hypotheses, disease stage (premanifest, early- or late-HD) did not
relate to increased risk of either clinician-rated or self-reported clinically significant suicide
ideation. This finding agrees with another study in HD that did not find a relationship
between TFC and suicidality [35], but appears inconsistent with other HD literature. Disease
stage may not relate to suicidal ideation in HD, however methodological differences
between this sample and other studies may explain this discrepancy. First, this study used
different measures to assess suicidal ideation. This study employed the PBA-s (a clinicianrated instrument that measures behavior over the last four weeks) and a single self-report
item about suicidal thoughts (within the past week), whereas other studies used the BDI-II to
assess suicidal thoughts (within the past 2 weeks), the UHDRS assessment of suicidal
thoughts and attempts over the past six months, and the C-SSRS which assesses lifetime
suicidal thoughts and attempts.

Author Manuscript

Our findings suggest that other than gender, demographic factors may not play a major role
in suicidal ideation in this population. Findings from the National Comorbidity Survey
suggest that simply having a chronic illness increases one’s risk of suicidal ideation [38]. In
addition, a study conducted within the Mental Health Research Network found that 17 of 19
physical health conditions were associated with an increased risk of suicide and having
multiple physical health conditions significantly increased suicide risk [39]. Thus our sample
may have been more affected by just having a chronic disease, rather than the severity of
their HD (i.e., disease stage). The high risk of suicide in individuals with HD likely reflects
the lack of an available cure to this relentlessly progressive condition [1, 2]. Alternatively,
individuals with clinically significant suicide ideation may not share their distress either in
person or via self-report survey, because they do not want help [40, 41] or to avoid
involuntary hospitalization [42, 43]. In addition, clinician-rated risk and self-reported risk
yield similar, but not identical, findings; thus further examination of demographic factors
such as gender and Hispanic ethnicity warrant further exploration in HD.
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As expected clinician-rated depression and anger related to greater risk for clinically
significant suicide ideation. Only depression remained a significant risk factor for clinically
significant suicidal thoughts whereas other self-reported symptoms did not. The relationship
between depression and suicidal ideation in HD resembles the strong relationship found in
both the HD population [34, 44] as well as other populations [22, 23, 45]. Also not
surprisingly, anger related to suicide risk in HD, as it does in other groups [23, 46].
Interestingly, self-reported risk did not reveal this relationship, perhaps suggesting that those
with HD are less apt to share or have less awareness of their own anger.

Author Manuscript

In general, individuals with HD were more likely to endorse suicidal ideation via self-report
than via in-person interview similar to other groups [18, 19]. Finally, although clinicianrated measures reasonably agreed with self-reported suicidal ideation (with substantial
agreement for premanifest participants), clinician-rated suicide significance did not agree
with self-reported suicide actionable risk. This suggests that these assessment modalities
identify different individuals that need intervention. Thus both assessment modalities should
be considered to maximize identification of those most likely to engage in a suicide plan.
The current study found that female gender and Hispanic/Latino ethnicity related to an
increased occurrence of suicidal ideation in premanifest and manifest HD. Additional factors
to consider in evaluating suicide risk in HD (which were not assessed in the current study)
include substance dependence, psychiatric history, hopelessness, irritability, emotional
distress, sleep disturbance, ego strength, suicidal ideation, history of suicide attempts,
unemployment, motor status, and social dysfunction [23, 39, 45, 47–50]. All should be
considered when determining best practices for evaluation of suicidal ideation in this
population.

Author Manuscript

Future research should focus on the identification of existing HD suicide risk assessment
practices within clinical and research settings. A goal of this research should be to develop
formal guidelines for best practices and a standardized assessment for suicide risk in those
individuals that are at risk for or have premanifest or manifest HD. The findings from this
study would suggest that best practices for assessment of risk should include multiple
assessment modalities to ensure that those individuals that are experiencing these thoughts
and feelings are identified and provided with appropriate interventions. The goal should be
to maximize the identification of those at-risk and thus ensure that all individuals with
suicidal ideation are identified, as the potential consequence of not identifying someone is
death.

Author Manuscript

While these findings have important implications for assessing suicidal ideation and
clinically significant suicide in HD, we recognize several study limitations. First, we
examined thoughts of suicide and suicide plans but did not have consistent data about past
history of suicide attempts. A past history of suicide attempt confers a significant risk factor
for future attempts in the general population [51], and future work could determine if this
holds for HD. In addition, the online and clinician-rated assessments were not identical. The
clinician measure provided numerical descriptions for frequency (e.g., once per week, every
day) while the online assessment had qualitative options (e.g., rarely, or sometimes).
Therefore, participants may have interpreted the online assessment differently from other
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participants or the clinician measure. In addition, the demographics of our sample may limit
the generalizability of our findings. Our sample was highly educated in comparison to the
general population, and was primarily white as evident by the small proportion of African
American (1.8%) and Hispanic/Latino (2.4%) participants. While the CDC estimates for
suicidal ideation for White, non-Hispanic participants was only slightly above the overall
estimate (3.9% compared to 3.7%), the homogenous makeup of our sample must be
considered when interpreting our comparisons to the general population. Furthermore, the
small proportion of Hispanic participants in our study, as well as the small number of
participants who endorsed clinically significant suicide ideation on the survey (N = 10) may
have altered the results of the logistic regression model. On the survey, 2 Hispanic
participants (17%) had clinically significant suicidal ideation compared to 8 non-Hispanic
participants (1.7%), thus a single Hispanic participant who endorses suicidal plans held
more weight than a single non-Hispanic participant.

Author Manuscript
Author Manuscript

As expected, rates of suicide in HD significantly exceed that in the general population.
Furthermore, the typical demographic risk factors for suicidal ideation in the general
population were not apparent in this HD sample. Thus, having premanifest or manifest HD
warrants increased attention to suicide risk; therefore, clinicians should feel comfortable
raising concerns about suicide with their patients to provide or refer to appropriate clinical
services. Furthermore, symptoms of depression and anger also should alarm clinicians to
further investigate feelings of suicide with their patients. Finally, clinicians should use
multiple modes of assessment for suicidal ideation since self-report surveys and in-person
interviews identified different individuals with clinically significant suicidal ideation. The
threshold for concern should be low to maximize identification of those with suicidal
ideation. This extra effort to identify those extremely distressed individuals with greater risk
for suicide may save lives.
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ABBREVIATIONS
ADL

Activities of Daily Living

CAG

Cytosine-Adenine-Guanine Trinucleotide DNA repeats

HD

Huntington disease

HDQLIFE Huntington Disease Health-Related Quality of Life
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HRQOL

Health-related Quality of Life

MMWR

Morbidity and Mortality Weekly Report (published by Centers for Disease
Control)

PBA-s

Problem Behaviors Assessment-short

TFC

Total Functional Capacity UHDRS Unified Huntington Disease Rating Scale
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Demographic Characteristics of Individuals with HD, stratified by disease stage
Variable

Premanifest (N = 194)

Stage I (N = 79)

Stage II (N = 113)

Stage III-V (N = 110)

All (N = 496)

42.7 (12.1)

51.1 (13.5)

52.4(11.7)

54.7(11.9)

48.9 (13.2)

Female

63.9

49.4

58.4

58.2

59.1

Male

36.1

50.6

41.6

41.8

40.9

White

97.4

96.2

98.2

93.6

96.6

African American

0.0

0.0

0.0

6.4

1.8

Other

2.1

3.8

1.8

0.0

1.4

Not Provided

0.5

0.0

0.0

0.0

0.2

Not Hispanic or Latino

92.7

89.9

94.7

96.8

93.6

Hispanic or Latino

1,5

6.3

2.7

0.8

2.4

Not Provided

5.9

3.8

2.7

2.4

4

15.9 (2.9)

15.4(3.1)

14.3 (2.5)

14.2 (2.6)

15.1 (2.9)

Single, Never Married

16.5

16.5

14.3

10.9

14.8

Married

67.0

51.9

54.5

62.7

60.8

Separated/Divorced

13.9

21.5

25.9

22.7

19.8

Widowed

0.0

2.5

3.6

3.7

2.0

Living with Partner

2.6

7.6

1.8

0.0

2.6

42.1 (2.9)

43.4 (4.5)

42.8 (3.3)

44.4 (6.9)

42.8 (4.1)

Age (years)
M(SD)
Gender (%)

Race (%)

Author Manuscript

Ethnicity (%)

Education (# of years)
M(SD)
Marital Status (%)

Author Manuscript

CAG Repeats
M (SD)

Author Manuscript
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Odds Ratios for Individuals with Clinically Significant Suicidal Ideation
OR

95% CL

P

Depression

1.44

(1.21, 1.71)

<0.0001

Anger/Aggression

1.21

(1.00, 1.46)

0.05

Anxiety

1.01

(0.87, 1.18)

0.85

Gender

8.21

(0.88,76.53)

0.06

Clinician-Rated Measure

Self-Report Measure
Depression

1.19

(1.02, 1.38)

0.04

Hispanic or Latino

9.23

(1.08,78.53)

0.04

<0.001

(<0.001, >999.99)

0.98

Ethnicity not Provided

Author Manuscript
Author Manuscript
Author Manuscript
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Author Manuscript
2.1%

2.1%
0.5%

Often

Clinically Significant Suicidal Ideation (% Yes)

1.5%

2.6%

Sometimes

Always

2.1%

4.6%

1.5%

3.1%

7.7%

90.2%

85.1%

Survey

Rarely

PBA-s

Never

Frequency (%)

Premanifest (n = 194)

2.5%

0.0%

0.0%

3.8%

10.1%

86.1%

PBA-s

3.8%

2.5%

1.3%

3.8%

13.9%

78.5%

Survey

Stage I (n = 79)

1.8%

1.8%

0.0%

4.4%

5.3%

88.5%

PBA-s

0.9%

0.0%

1.8%

7.1%

13.3%

77.9%

Survey

Stage II (n = 113)

3.6%

0.9%

0.9%

1.8%

7.3%

89.1%

PBA-s

2.7%

2.7%

4.5%

7.3%

10.0%

75.5%

Survey

Stage III-V (n = 110)

Author Manuscript

Proportions of Suicidal ideation for Clinician Rated and Self-Reported Assessments

2.4%

0.8%

1.0%

3.0%

6.3%

88.9%

PBA-s

2.0%

1.8%

2.4%

5.0%

10.5%

80.2%

Survey

All (n = 496)

Author Manuscript
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Kappa (k) coefficients comparing agreement between the clinician rated measure and self-report measure
Frequency

Clinically Significant Suicidal Ideation

Premanifest

0.3214

0.6296

Stage I

0.3850

-0.1538

Stage II

0.1750

-0.0541

Stage III-V

0.3140

0.1818

All

0.2678

0.2031

Author Manuscript
Author Manuscript
Author Manuscript
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